Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Prospective double-blind, randomized phase III ENGOT-EN5/GOG-3055/SIENDO study of oral selinexor/placebo as maintenance therapy after first-line chemotherapy for advanced or recurrent endometrial cancer

ESMO Virtual Plenary

Session date: 17-18 March 2022

Login to get immediate access to this content.

Login

Abstract

VP2-2022: Prospective double-blind, randomized phase III ENGOT-EN5/GOG-3055/SIENDO study of oral selinexor/placebo as maintenance therapy after first-line chemotherapy for advanced or recurrent endometrial cancer

Published: March 17, 2022
DOI: https://doi.org/10.1016/j.annonc.2022.02.223
Download PDF

I.B. Vergote; A. Pérez Fidalgo; E. Hamilton; S. Shacham; M.R. Mirza; V. Makker
Show authors and affiliations

Background

Patients (pts) with first-line metastatic or recurrent endometrial cancer (EC) are usually treated with paclitaxel and carboplatin but most have short-term disease control and a poor prognosis. Selinexor (SEL) inhibits XPO1 resulting in nuclear accumulation of p53, and has shown clinical activity in previously treated, advanced EC.

Methods

ENGOT-EN5/GOG-3055/ SIENDO (NCT03555422) is a prospective, multicenter, double-blind, placebo (PLB)-controlled, phase III study that evaluated SEL (80mg once weekly) vs PLB as maintenance therapy in pts with advanced or recurrent EC in partial or complete remission after taxane-platinum combination therapy. Primary endpoint compared progression-free survival (PFS) of SEL vs PLB, using a 2-sided stratified log-rank test. HR and the corresponding 2-sided 95% CI were estimated using stratified Cox proportional hazards model adjusting for stratification factors: primary stage IV disease vs recurrent disease at the start of combination chemotherapy and partial or complete response after chemotherapy.

Results

263 pts were randomized 2:1 to SEL (n=174) or PLB (n=89). Baseline characteristics were well balanced. Median follow up was 10.2 months (mo). The stratification adjusted analysis of PFS resulted in a HR of 0.705 (95% CI 0.499-0.996), p=0.048 (median 5.7 mo SEL vs 3.8 mo PLB). Subgroup analysis of EC pts with TP53wt showed a PFS of 13.7 mo with SEL and 3.7 mo with PLB (HR= 0.375, 95% CI 0.210-0.670, p=0.0006). Pts with MSS/pMMR disease had a PFS of 6.9 mo with SEL and 5.4 with PLB (HR= 0.593, 95% CI 0.388-0.905, p=0.014). Most common adverse events (AEs) (SEL/PLB) were nausea (83.6%/34.1%), vomiting (51.5%/17.0%), and constipation (37.4%/37.5%). Most AEs were low grade and reversible. Discontinuations due to AEs were 10.5% SEL and 1.1% PLB.

Conclusions

These results demonstrate that patients with advanced or recurrent EC administered once-weekly oral SEL have prolonged PFS compared to PLB with a manageable and tolerable safety profile. Pre-specified subgroup analyses identified wild-type TP53 and pMMR as important predictors of SEL efficacy.

Clinical trial identification

NCT03555422.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.